PRISM BioLab Co. LTD (JP:206A)
:206A
206A Stock Chart & Stats
¥160.00
-¥4.00(-1.25%)
At close: 4:00 PM EST
¥160.00
-¥4.00(-1.25%)
Day’s Range― - ―
52-Week Range¥132.00 - ¥288.00
Previous CloseN/A
Volume305.30K
Average Volume (3M)2.26M
Market Cap
¥6.61B
Enterprise Value¥3.22B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.95
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.74
Shares Outstanding36,934,000
10 Day Avg. Volume1,556,930
30 Day Avg. Volume2,256,993
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.27
Price to Sales (P/S)9.06
P/FCF Ratio-4.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially lowers solvency risk and preserves strategic optionality for a pre-commercial biotech. It supports continued R&D spending, partner-friendly licensing deals, or time to raise capital on better terms, reducing near-term liquidity pressure.
Strong Recent Revenue GrowthSustained top-line growth indicates growing demand for PRISM BioLab's discovery services or partnered programs. For a platform/discovery company, rising revenue improves the odds of future milestone receipts and validates commercial interest in its technologies.
Partnering/licensing Business ModelA licensing/partnering model shifts development cost and clinical risk to collaborators while providing non-dilutive cash inflows (upfronts, research fees, milestones). This model can accelerate programs and monetize technology earlier than full solo commercialization.
Bears Say
Persistent Net LossesMulti-year operating and net losses erode retained equity and limit reinvestment capacity. Persistent negative profitability means the company must continually secure external funding or partnerships to sustain R&D and operations, raising execution and dilution risk.
Weak Cash Generation / Cash BurnDeteriorating operating and free cash flows increase funding vulnerability for a development-stage biotech. Accelerating cash burn shortens the runway, forces financing decisions sooner, and can constrain the ability to advance programs independently without partner support.
Margin Compression & High Operating CostsCompressed gross margins and high operating costs mean revenue growth has not translated to sustainable profitability. If structural cost bases remain elevated, scaling revenue alone may be insufficient to restore positive cash flow or attractive returns for shareholders.
PRISM BioLab Co. LTD News
206A FAQ
What was PRISM BioLab Co. LTD’s price range in the past 12 months?
PRISM BioLab Co. LTD lowest stock price was ¥132.00 and its highest was ¥288.00 in the past 12 months.
What is PRISM BioLab Co. LTD’s market cap?
PRISM BioLab Co. LTD’s market cap is ¥6.61B.
When is PRISM BioLab Co. LTD’s upcoming earnings report date?
PRISM BioLab Co. LTD’s upcoming earnings report date is May 20, 2026 which is in 47 days.
How were PRISM BioLab Co. LTD’s earnings last quarter?
PRISM BioLab Co. LTD released its earnings results on Feb 13, 2026. The company reported -¥7.74 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.74.
Is PRISM BioLab Co. LTD overvalued?
According to Wall Street analysts PRISM BioLab Co. LTD’s price is currently Overvalued.
Does PRISM BioLab Co. LTD pay dividends?
PRISM BioLab Co. LTD does not currently pay dividends.
What is PRISM BioLab Co. LTD’s EPS estimate?
PRISM BioLab Co. LTD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PRISM BioLab Co. LTD have?
PRISM BioLab Co. LTD has 36,934,000 shares outstanding.
What happened to PRISM BioLab Co. LTD’s price movement after its last earnings report?
PRISM BioLab Co. LTD reported an EPS of -¥7.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.518%.
Which hedge fund is a major shareholder of PRISM BioLab Co. LTD?
Currently, no hedge funds are holding shares in JP:206A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PRISM BioLab Co. LTD
PRISM BioLab Co., LTD (206A) is a biotechnology company specializing in the discovery and development of small molecule drugs. The company focuses on innovative structural biology techniques to develop novel therapeutic agents targeting a range of diseases. Its core products include proprietary compounds aimed at addressing unmet medical needs in areas such as oncology and inflammatory diseases.
Technical Analysis
StemRIM Inc.
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―